NEW CANAAN, CT, January 30, 2006—The Board of Trustees of the Albert B. Sabin Vaccine Institute (Sabin) announced personnel changes made to strengthen the Institute’s efforts in the area of cancer vaccines. At a January 12 meeting in New York, the Board elected Axel Hoos, MD, PhD, as a trustee and approved the appointment of Robert Allen, MD, as vice president for cancer programs.
Achieving success in the global fight against the "big three" diseases-HIV/AIDS, tuberculosis and malaria, which together account for 5.6 million deaths a year-may well require a concurrent attack on the world's most neglected tropical diseases, says a team of researchers in the international open access journal PLoS Medicine.
Achieving success in the global fight against the "big three" diseases-HIV/AIDS, tuberculosis an
WASHINGTON, D.C., Sept. 7, 2005 – The Albert B. Sabin Vaccine Institute (Sabin), a leader in promoting the development and use of safe and effective vaccines to prevent disease, announced receipt of a grant of $150,000 from the Bill & Melinda Gates Foundation for the sponsorship of a vaccine policy colloquium to be held at Cold Spring Harbor, Long Island, New York, October 19-21, 2005.
NEW CANAAN, CT—Thirty-five leading cancer vaccine researchers met to consider medical progress in treating cancer with vaccines during a three-day meeting convened by New Canaan’s Sabin Vaccine Institute (Sabin) held this past June.
NEW CANAAN, CT, JUNE 29, 2005 —The Sabin Vaccine Institute will recognize extraordinary contributors to disease research and healthcare innovations at its black-tie gala beginning at 6:30 p.m. on June 29, 2005 at the University Club in New York City.